AIM VACCINE (06660) announced that the on-site work for the Phase III clinical trial of its high-potency human diploid rabies vaccine, developed using an iterative process, has been successfully completed. This milestone signifies the vaccine's official entry into a new stage, laying a solid foundation for its future commercial launch. This product is an iteratively upgraded human diploid rabies vaccine, distinguished by its notably ultra-high potency, representing a major iterative upgrade in the global rabies vaccine technology sector. Animal studies have demonstrated that the company's human diploid rabies vaccine induces antibodies with a high level of protection post-immunization; under the same dosage conditions, its potency is significantly higher than that of already marketed human diploid rabies vaccines. Rabies has the highest fatality rate of any disease worldwide; once symptoms appear, the mortality rate approaches 100%. Currently, there is a lack of effective clinical treatments for rabies, making post-exposure prevention critical, with vaccination being the primary preventive measure. Compared to traditional Vero cell rabies vaccines, human diploid rabies vaccines use human diploid cells instead of Vero cells; these cells are homologous to humans, offering inherent safety advantages. Currently, human diploid rabies vaccines on the market are priced 3 to 5 times higher than Vero cell rabies vaccines, indicating higher product added value. Compared to traditional first-generation human diploid rabies vaccines, the company's iteratively developed high-potency version has pioneered a breakthrough in overcoming the technical bottlenecks of low virus titer and low yield inherent in traditional processes. Through optimized and innovative purification techniques, both product quality and safety have been significantly enhanced. This achievement not only showcases the company's R&D capabilities but also marks a significant breakthrough in the field of high-potency processes for rabies vaccines globally. China is the world's largest rabies vaccine market. According to CIC statistics, driven by product upgrades and increasing adoption of rabies vaccines, the market is projected to reach RMB 14.8 billion by 2030. Compared to traditional rabies vaccination schedules, the company's product offers greater flexibility and convenience in administration, supporting not only the "five-dose" regimen but also the "simplified four-dose" and "2-1-1 four-dose" regimens. According to the "Rabies Exposure Prevention and Treatment Guidelines (2023 Edition)" issued by China's National Disease Control and Prevention Administration and the National Health Commission, rabies vaccination clinics are required to stock at least two different types of rabies vaccines. The company's product, with its iterative technological advantages and flexible administration options, is well-positioned to become a preferred choice for vaccination providers. The company has constructed a workshop for the high-potency human diploid rabies vaccine that fully meets international standards and has completed the production of commercial-scale samples for the Phase III clinical trial, demonstrating its capability for large-scale manufacturing of this product. Human diploid rabies vaccines are recommended by the WHO as the gold standard for rabies vaccination and are widely used in many developed countries. As the world's second-largest supplier of rabies vaccines, the company is committed to leading deep technological iterative upgrades in the global rabies vaccine sector. It aims to provide the market with a series of rabies vaccine products offering better quality and higher safety, thereby further consolidating its leading position in the global rabies vaccine field and promoting the group's sustainable development. Future approval of this product will further enrich the company's product portfolio, creating synergies with its existing rabies vaccine series and enhancing its core competitiveness. As part of its global strategy, the vaccine is expected to contribute additional revenue, strengthen the company's market position, and provide new momentum for its sustained and stable growth.